Both bevacizumab and ranibizumab were originally developed by the same company, Genentech.
Notes on verification
Multiple independent sources including drug approval histories, clinical trial registries, and a first-hand account by a key researcher confirm both drugs were developed by Genentech, with ranibizumab derived from the same antibody as bevacizumab.
Sources
- Procedura di infrazione da parte dell'Autorità Antitrust (epicentro.iss.it)
- https://www.drugs.com/history/avastin.html (drugs.com)
- https://clinicaltrials.gov/study/NCT01127360 (clinicaltrials.gov)
- https://retinatoday.com/articles/2009-may-june/0609_05-php (retinatoday.com)
- https://gabionline.net/biosimilars/general/Biosimilars-of-ranibizumab (gabionline.net)
- https://www.biospace.com/fda-approves-genentech-s-lucentis-ranibizumab-injection-0-3-mg-prefilled-syringe-for-diabetic-macular-edema-and-diabetic-retinopathy (biospace.com)
- https://www.drugs.com/history/lucentis.html (drugs.com)